https://orcid.org/0000-0002-5017-3546
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Aim: This meta-analysis was performed to assess the efficacy and safety of mavacamten in patients with hypertrophic cardiomyopathy. Methods & materials: A search was conducted using PubMed, Cochrane, and Scopus up to August 2022 for randomized studies reporting our pre-specified outcomes. Results: It was observed that mavacamten significantly improved New York Heart Association class (p < 0.009), Clinical Summary Score of the Kansas City Cardiomyopathy Questionnaire (p = 0.02), post-exercise left ventricular outflow tract gradient (p < 0.00001), functional end point (p = 0.05), and lowered septal reduction therapy rates (p < 0.00001). However, there were no significant differences in the ≥1 severe adverse events, ≥1 treatment-emergent adverse events, left ventricular volume index, left ventricular filling pressure, left ventricular end-diastolic volume index, and peak oxygen uptake (pVO2). Conclusion: Future large-scale trials are required to confirm our results and determine the long-term benefits and risks of mavacamten use in these patients.
Plain Language Summary
Mavacamten is a recently introduced medication that relaxes the heart muscle and is indicated for patients with hypertrophic cardiomyopathy (a disease in which parts of the heart become thick and stiff). To determine the effectiveness and safety of this drug, the results of clinical trials were combined in order to produce an overall estimate. Overall, it was observed that mavacamten improved most functional parameters related to the heart and demonstrated no significant increases in the number of side effects. This suggests the effectiveness and safety of mavacamten, although further trials are needed to confirm our results.
Tweetable abstract
The efficacy and safety of mavacamten, a novel drug, was assessed in patients of hypertrophic cardiomyopathy. It was noted that mavacamten significantly improved NYHA class, KCCQ-CSS score, post-exercise LVOT gradient, functional end point, and lowered SRT rates.
Graphical abstract
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at:www.tandfonline.com/doi/suppl/10.2144/fsoa-20s23-0059
Author contributions
Conceptualization: A Memon; methodology: Z Khan, A Irfan; formal analysis and investigation: A Memon, M Urooj, M Faisal; writing – original draft preparation: A Memon, MO Larik, Z Khan, M Urooj, A Irfan, B Kumari, M Faisal, M Tehrim, R Siddiqui; writing – review, editing and critical revision of work: A Memon, MO Larik, I Hameed; Supervision: I Hameed. All authors have approved the final version of this manuscript.
Acknowledgments
The authors acknowledge the Research Council of Pakistan (RCOP) for supporting all aspects of conducting this study.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.